Hepatitis C Virus Infection Market SWOT Analysis by Key Players: Roche Diagnostics, Abbott, Siemens

HTF MI added a new research study in its database with title 'Therapeutic Class Report Overview : Hepatitis C Virus Infection ' that includes detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions like South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico) and important players/vendors such as Roche Diagnostics,Abbott,Siemens,Qiagen,bioMérieux,Bio-Rad Laboratories, Meridian Bioscience,Vista Diagnostics,Biogate Laboratories,J.Mitra & Co. Ltd,Siemens Medical,General Biologicals.The report will help user gain market insights, future trends and growth prospects for forecast period of 2020-2026.

Request a sample report @ https://www.htfmarketreport.com/sample-report/2827070-therapeutic-class-report-overview

Summary
The launch of Protease inhibitors’ (PIs) created a wave in 2011-12 and accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations have raised the bar and the expectations of pts, physicians and investors. Freedom from IFN, treating all genotypes and betting on vaccines could bring a sea of change in the HCV therapy class area in the future.
Roche set the trend with the acquisition of Anadys for total of $230m followed by GILD buying VRUS for $11b, Bristol-Myers Squibb (BMY) acquired Inhibitex for $2.5b, VRTX acquired Virochem in 2009 for $375m + in-licensed Alios’ VX-135 in 2012 for total of $775m, and Abbott in-licensed Enanta’s ABT-450 for total of ~$310m. In the next spurt of M&A in this sector, we expect companies which offer differentiated MOA to be in the limelight, are (i) Alleviate the need for Ribavarin, (ii) Address resistance, non-responders, Liver cirrhosis, HIV-HCV –co infection etc, (iii) Target other genotypes, and (iv) Vaccines or Boosters of immune system (toll like receptors). In this report, we have analyzed the novel pipeline candidates, which target unmet needs, offer promise of an ‘all oral IFN-free treatment’ with at par or better efficacy / compliance, and novel vaccine candidates.

Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/2827070-therapeutic-class-report-overview

The launch of Protease inhibitors’ (PIs) created a wave in 2011-12 and accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations have raise

....Continued

View Detailed Table of Content @ https://www.htfmarketreport.com/reports/2827070-therapeutic-class-report-overview

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Place a Purchase Order For Market Study (Single User License) at: https://www.htfmarketreport.com/buy-now?format=1&report=2827070

Contact US :
Craig Francis (PR & Marketing Manager)
HTF Market Intelligence Consulting Private Limited
Unit No. 429, Parsonage Road Edison, NJ
New Jersey USA – 08837
Phone: +1 (206) 317 1218
sales@htfmarketreport.com

Connect with us at LinkedIn | Facebook | Twitter

About Author:
HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”.

This release was published on openPR.